Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Wall Street Zen

Anixa Biosciences (NASDAQ:ANIX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

Several other research analysts also recently issued reports on ANIX. Citigroup reaffirmed a “buy” rating on shares of Anixa Biosciences in a report on Tuesday, October 6th. Zacks Research lowered shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. HC Wainwright cut their price target on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, September 22nd. Finally, Weiss Ratings upgraded Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Anixa Biosciences Price Performance

Shares of Anixa Biosciences stock opened at $3.12 on Friday. The firm has a fifty day moving average price of $2.97 and a 200 day moving average price of $2.97. The stock has a market cap of $108.45 million, a PE ratio of -9.75 and a beta of 0.47. Anixa Biosciences has a 1 year low of $2.32 and a 1 year high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings results on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). As a group, equities analysts expect that Anixa Biosciences will post -0.31 EPS for the current year.

Insider Buying and Selling at Anixa Biosciences

In other news, Director Lewis Titterton, Jr. purchased 49,036 shares of the company’s stock in a transaction dated Wednesday, September 23rd. The shares were purchased at an average price of $2.69 per share, for a total transaction of $131,906.84. Following the transaction, the director owned 1,046,003 shares of the company’s stock, valued at approximately $2,813,748.07. This trade represents a 4.92% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have acquired a total of 100,536 shares of company stock worth $275,737 over the last quarter. Insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

Several hedge funds have recently bought and sold shares of the business. Sanctuary Advisors LLC acquired a new stake in Anixa Biosciences in the second quarter valued at approximately $29,000. Northwestern Mutual Wealth Management Co. purchased a new position in Anixa Biosciences in the second quarter valued at about $29,000. Integrated Wealth Concepts LLC bought a new position in Anixa Biosciences in the 2nd quarter worth about $30,000. Simplicity Wealth LLC acquired a new stake in shares of Anixa Biosciences during the second quarter worth $34,000. Finally, NewEdge Wealth LLC acquired a new position in shares of Anixa Biosciences during the 2nd quarter worth $35,000. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. The company’s programs are designed to use the immune system to identify and attack disease-associated targets.

Anixa’s oncology pipeline has included a chimeric antigen receptor T-cell (CAR-T) therapy targeting the follicle-stimulating hormone receptor, which is being investigated as a potential treatment for ovarian cancer and other cancers.